Thank you for your interest. Give here your contact details and you'll receive an email with the pdf file you request.
Sign up to our monthly newsletter to receive our news.
Capital increase of 7.3 million euros for Kiomed Pharma, a spin-off of the University of Liège
KiOmed Pharma announces the completion of a significant strengthening of its balance sheet, up to 7.3 million EUR by issuing new shares up to 6.1 million EUR, and by obtaining an investment loan of another 1.2 million EUR from the Belfius Bank and BNP Paribas Fortis. The historic shareholders (Valois (Mestdagh and Montulet families) Meusinvest, KitoZyme and the founders Mr. François Blondel and Prof. Yves Henrotin) subscribed to an increase in capital of more than 2 million EUR, with the amount provided by the new shareholders: two Belgian industrialists associated with SRIW. “We are extremely pleased with this transaction, the largest in the young history of our company. With this new financial contribution, we now have the opportunity to finance the clinical study of our first product intended to treat osteoarthritis. We believe we have a product that has the potential to revolutionize the implants market based on hyaluronic acid. A market that exceeded 5 billion EUR in 2015. KiOmed is now well equipped to strengthen its local presence and succeed in its international ambitions”, said Mr. François Blondel, co-founder and Chairman of the Board. This capital increase allows KiOmed to turn to higher-value markets and to achieve a lasting and sustainable growth. “In just over two years, we have developed and industrialized a pipeline of biocompatible proprietary products meeting the most stringent standards, such as ultra-pure chitosan gel. This innovation will be the first in a series that will allow our fungal chitosan to treat more effectively patients with incapacitating often incurable diseases such as osteoarthritis,”added Mr. Houtai Choumane CEO KiOmed Pharma.
In collaboration with a team at the University of California at Los Angeles (UCLA), researchers from GIGA-Neurosciences have discovered a new gene responsible for a seizure syndrome called juvenile myoclonic epilepsy (JME). This discovery was made as part of an international consortium that studies genetic abnormalities responsible for epileptic diseases. It is being published this week in
The LIGHTSHEET MICROSCOPY can deliver optical sections, 3D reconstructions and timelapse movies of whole sample volumes at subcellular resolutions. The fast scan speeds and low phototoxicity of the lightsheet allow to record the development of fluorescent transgenic animals over long time periods, such as zebrafish embryos. Alternatively 3D reconstructions of fixed whole organs or whole embryos,
The researchers discovered that this cellular dialogue controls the growth of the cerebral cortex and that its impairment leads a cortical malformation previously associated with autism in mice . Their results are published in the prestigious scientific journal Cell. The cerebral cortex contains excitatory and inhibitory interneurons. The former are produced locally and move by